Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Int Med Res ; 18(6): 468-72, 1990.
Artigo em Inglês | MEDLINE | ID: mdl-2292328

RESUMO

Treatment of both male and female rats with 5 IU/day mepartricin for 7-10 days administered by gastric tubing resulted in an increased faecal excretion of some steroids. Mean rate of elimination of total oestrogens was enhanced by 45% in male rats and by 14% in female rats, and the average excretion of conjugated oestrogen was also increased in the female animals. Faecal elimination of cholesterol was 37% and 42% higher in male and female rats, respectively, after mepartricin treatment, and in male rats plasma concentrations of cholesterol were reduced following treatment. It is suggested mepartricin acts either by changing the intestinal flora or by acting directly on the steroid moieties, and it is speculated that a similar mechanism may occur in man.


Assuntos
Estrogênios/metabolismo , Fezes/química , Mepartricina/farmacocinética , Testosterona/metabolismo , Administração Oral , Animais , Colesterol/metabolismo , Feminino , Intubação Gastrointestinal , Masculino , Mepartricina/administração & dosagem , Ratos , Ratos Endogâmicos
2.
J Int Med Res ; 17(3): 212-7, 1989.
Artigo em Inglês | MEDLINE | ID: mdl-2504629

RESUMO

Mepartricin was given to cirrhotic patients in order to evaluate its effect on the imbalance of sex steroids which is typical of this disorder. Patients were divided into two group: one group received placebo (n = 19) and the other received 150,000 IU/day mepartricin for 30 days (n = 19). The patients were evaluated by separate medical staff who were unaware of the treatment. Mepartricin significantly decreased the plasma concentration of testosterone, oestradiol and prolactin as compared with the values at the start of the trial, while no significant changes were seen in the occurrence of gynaecomastia. No relevant changes were seen in patients receiving the control, except for a slight increase in the peripheral concentration of androstenedione, aldosterone and follicle stimulating hormone.


Assuntos
Androgênios/sangue , Estrogênios/sangue , Cirrose Hepática/tratamento farmacológico , Mepartricina/uso terapêutico , Polienos/uso terapêutico , Aldosterona/sangue , Ensaios Clínicos como Assunto , Hormônio Foliculoestimulante/sangue , Ginecomastia/sangue , Ginecomastia/etiologia , Humanos , Cirrose Hepática/sangue , Cirrose Hepática/complicações , Hormônio Luteinizante/sangue , Masculino , Prolactina/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...